• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Overview of the Port Delivery System with Ranibizumab

Opinion
Video

Margaret Chang, MD, examines the difficulties of frequent anti-VEGF injections and outlines the key aspects of the port delivery system (PDS) for ranibizumab administration.

  1. Why is sustained delivery of anti-VEGF necessary, and what challenges arise from frequent anti-VEGF injections?
  2. Can you provide an overview of the port delivery system with ranibizumab?
    1. How does the device function?
    2. How is the device implanted?
    3. How is the device refilled?
  3. What are the benefits of using the PDS with ranibizumab, and which patients are ideal candidates for this delivery method?
Related Videos
This series features 1 KOL.
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Related Content
RevOpsis, Kemwell Biopharma enter strategic partnership to expedite development of biologics for treatment of nAMD

RevOpsis, Kemwell Biopharma enter strategic partnership to expedite development of biologics for treatment of nAMD

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Podcast
4DMT presents injection-free subgroup analyses from Phase 2 PRISM randomized dose expansion cohort in wet AMD

4DMT presents injection-free subgroup analyses from Phase 2 PRISM randomized dose expansion cohort in wet AMD

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

Podcast
Avirmax Biopharma Inc receives IND approval from FDA

Avirmax Biopharma Inc receives IND approval from FDA

Article
Opthea completes enrollment in pivotal Phase 3 clinical program with sozinibercept in wet AMD

Opthea completes enrollment in pivotal Phase 3 clinical program with sozinibercept in wet AMD

Article
© 2024 MJH Life Sciences

All rights reserved.